FDA in recent months has been going the extra mile to aid Medtronic PLCin its regulatory development of a next-generation insulin pump-glucose monitor system, according to a company official
That has meant monthly, in-person meetings where agency officials provide detailed feedback on the company’s clinical plan, explains Patricia Shrader, Medtronic’s VP, Corporate Regulatory and External Affairs
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?